InvestSMART

Alterity Therapeutics Limited (ASX: ATH) - Share Price

- Current share price for ATH : $0.590

Alterity Therapeutics Limited (ATH, formerly Prana Biotechnology Limited), an ASX-listed company, is a clinical stage biotechnology company focused on neurodegenerative diseases. The company focusses to commercialise research into Parkinsonian movement disorders, Alzheimer disease, Huntington disease and other neurodegenerative disorders.

ATH General Information +

ASX Code ATH
Website http://www.alteritytx.com
Industry/Sector Biotechnology
Market Cap ($M) 128
ATH Share Price $0.590
Day High $0.600
Day Low $0.560
Last Close $0.590
ATH Share Price Movement - ( No change )
Prices as at 16:40, 17 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Alterity Therapeutics Limited (ATH) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Alterity Therapeutics Limited (ATH) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Alterity Therapeutics Limited (ATH) price-sensitive announcements

ATH - ATH Receives A$3.98m R&D Tax Incentive
Alterity Therapeutics Limited announced the receipt of A$3.98 million from the Australian
Alterity Therapeutics Limited (ATH)
9 Jul 2026 | 3:52 PM
ATH - FDA Meeting Minutes Confirm Registrational Path for ATH434
Alterity Therapeutics Limited announced that the FDA's official meeting minutes confirmed
Alterity Therapeutics Limited (ATH)
7 Jul 2026 | 9:44 AM
ATH - Alterity and FDA Agree on Phase 3 Program for ATH434 in MSA
Alterity Therapeutics Limited announced that they have achieved alignment with the U.S. FD
Alterity Therapeutics Limited (ATH)
9 Jun 2026 | 9:01 AM
ATH - Quarterly Activities/Appendix 4C Cash Flow Report
Alterity Therapeutics Limited is progressing its ATH434 program for treating Multiple Syst
Alterity Therapeutics Limited (ATH)
30 Apr 2026 | 9:53 AM

Alterity Therapeutics Limited (ATH) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Alterity Therapeutics Limited (ATH)
ORDINARY FULLY PAID
 Health Care $128 ATH Receives A$3.98m R&D Tax Incentive 9 Jul 2026 3:52PM $0.630 $0.590 fallen by 6.35%
Alterity Therapeutics Limited (ATH)
ORDINARY FULLY PAID
 Health Care $128 Application for quotation of securities - ATH 9 Jul 2026 11:40AM $0.600 $0.590 fallen by 1.67%
Alterity Therapeutics Limited (ATH)
ORDINARY FULLY PAID
 Health Care $128 FDA Meeting Minutes Confirm Registrational Path for ATH434 7 Jul 2026 9:44AM $0.710 $0.590 fallen by 16.90%
Alterity Therapeutics Limited (ATH)
ORDINARY FULLY PAID
 Health Care $128 Application for quotation of securities - ATH 1 Jul 2026 4:51PM $0.660 $0.590 fallen by 10.61%
Alterity Therapeutics Limited (ATH)
ORDINARY FULLY PAID
 Health Care $128 Change in substantial holding 30 Jun 2026 8:16AM $0.570 $0.590 risen by 3.51%
Alterity Therapeutics Limited (ATH)
ORDINARY FULLY PAID
 Health Care $128 Change of Director's Interest Notice x 2 17 Jun 2026 11:54AM $0.580 $0.590 risen by 1.72%

ATH Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2027F C2 -$7.10 35.10% 0.00 0.00 0.00% 0.0%
2026F C2 -$5.30 -53.00% 0.00 0.00 0.00% 0.0%
2025A -$14.35 -$11.20 -56.90% 0.00 0.00 0.00% 0.0%

ATH Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2025 A 2026 F 2027 F 2025 A 2026 F 2027 F 2025 A 2026 F 2027 F
Alterity Therapeutics Limited (ATH) $128M -0.5685 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
CSL Limited (CSL) $58,403M 0.1108 -0.1189 0.0168 13.0768 14.8421 14.5973 3.66% 2.99% 3.11%
Clinuvel Pharmaceuticals Limited (CUV) $510M 0.0287 0.0000 0.0000 14.0808 0.0000 0.0000 0.49% 0.00% 0.00%
Mesoblast Limited (MSB) $3,592M 0.0301 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,304M -1.3893 0.0000 -0.1300 0.0000 285.8974 328.6316 0.00% 0.00% 0.00%

ATH Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 2.54 0.00
Market 0.31 12.90 1.13 0.58
Sector 0.46 28.10 2.54 1.89

ATH Directors

Name Position Start Date
Dr David Stamler Chief Executive Officer, Managing Director 21 Nov 2025
Mr Julian Barbaczy Non-Executive Chairman, Non-Executive Director 21 Nov 2025
Mr Peter Ashley Marks Non-Executive Director 29 Jul 2005
Mr Lawrence Bernard Gozlan Non-Executive Director 8 Aug 2011
Ms Ann Cunningham Non-Executive Director 17 Apr 2026

Alterity Therapeutics Limited (ATH) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
7 Apr 2025 GOZLAN, Lawrence Buy Indirect Shares 4,545,455 $0.011 $50,000.000
7 Apr 2025 MELTZER, Brian Buy Direct Shares 2,272,727 $0.011 $25,000.000
7 Apr 2025 MARKS, Peter Buy Indirect Shares 1,818,182 $0.011 $20,000.000

See all changes in directors' interest & trades for Alterity Therapeutics Limited (ATH) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

ATH Management

Name Position
Abby Macnish Niven Company Secretary

ATH Calendar of Events

Date Event
25 February 2027 Report (Interim)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.